Charles Raymond Marmar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charles Raymond Marmar has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Duna Abu-Amara
Steven and Alexandra Cohen Veterans Center for Posttraumatic Stress and Traumatic Brain Injury, Department of Psychiatry, NYU, New York, United States
3 shared publicationsFirdaus S. Dhabhar
Department of Psychiatry & Behavioral Sciences, Sylvester Comprehensive Cancer Center, University of Miami, FL, United States
3 shared publicationsIouri Makotkine
James J. Peters Veterans Administration Medical Center Bronx, New York, United States; Icahn School of Medicine at Mount Sinai, New York, NY, United States
3 shared publicationsJanine D. Flory
James J. Peters Veterans Administration Medical Center Bronx, New York, United States; Icahn School of Medicine at Mount Sinai, New York, NY, United States
3 shared publicationsLinda M. Bierer
James J. Peters Veterans Administration Medical Center Bronx, New York, United States; Icahn School of Medicine at Mount Sinai, New York, NY, United States
3 shared publicationsMichelle Coy
Department of Psychiatry, University of California San Francisco (UCSF), School of Medicine, San Francisco, CA, United States
3 shared publications
Latest Publications
- Open Access
- 20 October 2020
- Published by American Medical Association (AMA) in JAMA
- Vol. 324 (15) , 1493-1494
Mental Health Disorders Related to COVID-19–Related Deaths
This Viewpoint discusses the mental health consequences of the coronavirus disease 2019 (COVID-19) pandemic and emphasizes the importance of developing a
- 20 October 2020
- Published by American Medical Association (AMA) in JAMA
- Vol. 324 (15) , 1493-1494
Open AccessMental Health Disorders Related to COVID-19–Related Deaths
This Viewpoint discusses the mental health consequences of the coronavirus disease 2019 (COVID-19) pandemic and emphasizes the importance of developing a
- Open Access
- 3 July 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (7) , 963
Distinct Profiles of Cell-Free MicroRNAs in Plasma of Veterans with Post-Traumatic Stress Disorder
Dysregulation of circulating microRNAs (miRNAs) in body fluids has been reported in psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and post-traumatic stress disorder (PTSD). Recent studies of various diseases showed that extracellular vesicles (EV) in body fluids can provide different spectra of circulating miRNAs and disease-associated signatures from whole fluid or EV-depleted fraction. However, the association of miRNAs in EVs to PTSD has not been studied. In this study, we performed a comprehensive profiling of miRNAs in whole plasma, extracellular vesicles (EV) and EV-depleted plasma (EVD) samples collected from combat veterans with PTSD and matched controls by utilizing a next-generation sequencing (NGS) platform. In total, 520 circulating miRNAs were quantified from 24 male Iraq and Afghanistan combat veterans with (n = 12) and without (n = 12) PTSD. The overall miRNA profiles in whole plasma, EV and EVD fractions were different and miRNAs affected by PTSD were also distinct in each sample type. The concentration changes of miR-203a-3p in EV and miR-339-5p in EVD were confirmed in an independent validation cohort that consisted of 20 veterans (10 with and 10 without PTSD) using qPCR. The target genes of these two miRNAs were involved in signaling pathways and comorbid conditions associated with PTSD (e.g., neurotransmitter systems such as dopaminergic and serotonergic signaling, inflammatory response, and cardiovascular diseases). Our findings suggest that PTSD may have different impacts on miRNAs encapsulated in vesicles and outside of vesicles. Further studies using larger samples are needed to evaluate the utility of these miRNAs as diagnostic biomarkers for PTSD.
- 3 July 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (7) , 963
Open AccessDistinct Profiles of Cell-Free MicroRNAs in Plasma of Veterans with Post-Traumatic Stress Disorder
Dysregulation of circulating microRNAs (miRNAs) in body fluids has been reported in psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and post-traumatic stress disorder (PTSD). Recent studies of various diseases showed that extracellular vesicles (EV) in body fluids can provide different spectra of circulating miRNAs and disease-associated signatures from whole fluid or EV-depleted fraction. However, the association of miRNAs in EVs to PTSD has not been studied. In this study, we performed a comprehensive profiling of miRNAs in whole plasma, extracellular vesicles (EV) and EV-depleted plasma (EVD) samples collected from combat veterans with PTSD and matched controls by utilizing a next-generation sequencing (NGS) platform. In total, 520 circulating miRNAs were quantified from 24 male Iraq and Afghanistan combat veterans with (n = 12) and without (n = 12) PTSD. The overall miRNA profiles in whole plasma, EV and EVD fractions were different and miRNAs affected by PTSD were also distinct in each sample type. The concentration changes of miR-203a-3p in EV and miR-339-5p in EVD were confirmed in an independent validation cohort that consisted of 20 veterans (10 with and 10 without PTSD) using qPCR. The target genes of these two miRNAs were involved in signaling pathways and comorbid conditions associated with PTSD (e.g., neurotransmitter systems such as dopaminergic and serotonergic signaling, inflammatory response, and cardiovascular diseases). Our findings suggest that PTSD may have different impacts on miRNAs encapsulated in vesicles and outside of vesicles. Further studies using larger samples are needed to evaluate the utility of these miRNAs as diagnostic biomarkers for PTSD.
- 1 December 2017
- Published by Elsevier in Psychiatry Research
- Vol. 258, 330-336
Increased circulating blood cell counts in combat-related PTSD: Associations with inflammation and PTSD severity
- 1 December 2017
- Published by Elsevier in Psychiatry Research
- Vol. 258, 330-336
Increased circulating blood cell counts in combat-related PTSD: Associations with inflammation and PTSD severity
- Top Cited Papers
- 22 June 2017
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 376 (25) , 2459-2469
Post-Traumatic Stress Disorder
PTSD is characterized by the persistence of intense reactions to reminders of a traumatic event, altered mood, a sense of imminent threat, disturbed sleep, and hypervigilance. Cognitive behavioral therapy and anxiolytic or antidepressant agents can ameliorate symptoms.
- 22 June 2017
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 376 (25) , 2459-2469
Top Cited PapersPost-Traumatic Stress Disorder
PTSD is characterized by the persistence of intense reactions to reminders of a traumatic event, altered mood, a sense of imminent threat, disturbed sleep, and hypervigilance. Cognitive behavioral therapy and anxiolytic or antidepressant agents can ameliorate symptoms.
- 1 June 2017
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 264, 76-81
Basal forebrain mediated increase in brain CRF is associated with increased cholinergic tone and depression
- 1 June 2017
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 264, 76-81
Basal forebrain mediated increase in brain CRF is associated with increased cholinergic tone and depression
- 1 January 2017
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 59, 260-264
Increased pro-inflammatory milieu in combat related PTSD – A new cohort replication study
- 1 January 2017
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 59, 260-264
Increased pro-inflammatory milieu in combat related PTSD – A new cohort replication study
- Open Access
- 25 April 2016
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 7, 72
Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder
Major Depressive Disorder (MDD) contributes to a significant worldwide disease burden, expected to be second only to heart disease by 2050. However, accurate diagnosis has been a historical weakness in clinical psychiatry. As a result, there is a demand for diagnostic modalities with greater objectivity that could improve on current psychiatric practice that relies mainly on self-reporting of symptoms and clinical interviews. Over the past two decades, literature on a growing number of putative biomarkers for MDD increasingly suggests that MDD patients have significantly different biological profiles compared to healthy controls. However, difficulty in elucidating their exact relationships within depression pathology renders individual markers inconsistent diagnostic tools. Consequently, further biomarker research could potentially improve our understanding of MDD pathophysiology as well as aid in interpreting response to treatment, narrow differential diagnoses, and help refine current MDD criteria. Representative of this, multiplex assays using multiple sources of biomarkers are reported to be more accurate options in comparison to individual markers that exhibit lower specificity and sensitivity, and are more prone to confounding factors. In the future, more sophisticated multiplex assays may hold promise for use in screening and diagnosing depression and determining clinical severity as an advance over relying solely on current subjective diagnostic criteria. A pervasive limitation in existing research is heterogeneity inherent in MDD studies, which impacts the validity of biomarker data. Additionally, small sample sizes of most studies limit statistical power. Yet, as the RDoC project evolves to decrease these limitations, and stronger studies with more generalizable data are developed, significant advances in the next decade are expected to yield important information in the development of MDD biomarkers for use in clinical settings.
- 25 April 2016
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 7, 72
Open AccessIs there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder
Major Depressive Disorder (MDD) contributes to a significant worldwide disease burden, expected to be second only to heart disease by 2050. However, accurate diagnosis has been a historical weakness in clinical psychiatry. As a result, there is a demand for diagnostic modalities with greater objectivity that could improve on current psychiatric practice that relies mainly on self-reporting of symptoms and clinical interviews. Over the past two decades, literature on a growing number of putative biomarkers for MDD increasingly suggests that MDD patients have significantly different biological profiles compared to healthy controls. However, difficulty in elucidating their exact relationships within depression pathology renders individual markers inconsistent diagnostic tools. Consequently, further biomarker research could potentially improve our understanding of MDD pathophysiology as well as aid in interpreting response to treatment, narrow differential diagnoses, and help refine current MDD criteria. Representative of this, multiplex assays using multiple sources of biomarkers are reported to be more accurate options in comparison to individual markers that exhibit lower specificity and sensitivity, and are more prone to confounding factors. In the future, more sophisticated multiplex assays may hold promise for use in screening and diagnosing depression and determining clinical severity as an advance over relying solely on current subjective diagnostic criteria. A pervasive limitation in existing research is heterogeneity inherent in MDD studies, which impacts the validity of biomarker data. Additionally, small sample sizes of most studies limit statistical power. Yet, as the RDoC project evolves to decrease these limitations, and stronger studies with more generalizable data are developed, significant advances in the next decade are expected to yield important information in the development of MDD biomarkers for use in clinical settings.
- Open Access
- 1 September 2015
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 72 (9) , 875-881
Course of Posttraumatic Stress Disorder 40 Years After the Vietnam War
Military personnel deployed to war zones are exposed to a broad array of traumatic events1,2 and are at risk for posttraumatic stress disorder (PTSD) and other readjustment problems. Posttraumatic stress disorder can be debilitating, especially when complicated by comorbid depression and substance use.3,4
- 1 September 2015
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 72 (9) , 875-881
Open AccessCourse of Posttraumatic Stress Disorder 40 Years After the Vietnam War
Military personnel deployed to war zones are exposed to a broad array of traumatic events1,2 and are at risk for posttraumatic stress disorder (PTSD) and other readjustment problems. Posttraumatic stress disorder can be debilitating, especially when complicated by comorbid depression and substance use.3,4
- 1 November 2014
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 42, 81-88
Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress
- 1 November 2014
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 42, 81-88
Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress
- 1 April 2010
- Published by American Psychological Association (APA) in Professional Psychology: Research and Practice
- Vol. 41 (2) , 135-142
The role of psychologists in the care of Iraq and Afghanistan veterans in primary care settings.
- 1 April 2010
- Published by American Psychological Association (APA) in Professional Psychology: Research and Practice
- Vol. 41 (2) , 135-142
The role of psychologists in the care of Iraq and Afghanistan veterans in primary care settings.